BioSante up on early data on GVAX pancreatic cancer vaccine with ipilimumab
This article was originally published in Scrip
Executive Summary
Shares of BioSante Pharmaceuticals rose after the company said that it saw improved overall survival in an early-stage trial of pancreatic cancer patients treated with its cancer vaccine, GVAX Pancreas, when in a combination trial. The shares closed at 81 cents, a gain of 10 cents or 14%, on 27 February.